LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Salminen, Seppo; Wright, Atte von (2011)
Publisher: Microbial Ecology in Health and Disease
Journal: Microbial Ecology in Health and Disease
Languages: English
Types: Article
Subjects:
Traditionally probiotics are defined as viable microorganisms (bacteria or yeasts) that have a beneficial effect on the health of the host. Probiotics are used in fermented dairy products, but also in other foods, clinical foods and pharmaceutical preparations and they are also increasingly used as added functional ingredients in non-fermented foods. The selection of new probiotic organisms targets on new strains and even genera that are more beneficial or specific. When totally novel microbes and genetically modified organisms are introduced, their safety and the risk-to-benefit ratio have to be carefully studied and assessed. Also, new probiotics should be of genera and strains commonly found in the healthy human intestinal microflora. Lactic acid bacteria in foods have a long history of safe use. Members of the genera Lactococcus and Lactobacillus are most commonly regarded as having the generally recognised safe status. Members of the genera Streptococcus and Enterococcus and also other genera of lactic acid bacteria include some opportunistic pathogens. The theoretical adverse effects of probiotics including potential acute effects, strain-dependent properties, intrinsic factors and the potential virulence are discussed. The available information supports the safety of currently used probiotics, but recommendations for the safety assessment of new probiotics are needed and proposed.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Salminen S, Gibson G, Bouley MC, Isolauri E, BoutronRualt MC, Moreau M-C, Cummings J, Franck A, Rowland I, Roberfroid M. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998; 80 (Suppl 1): S147 - 71.
    • 2. Jonas D, Abtignac E, Antoine J-M, Classen H-G, Huggett A, Knudsen I, Mahler J, Ockhuizen T, Smith M, Teuber M, Walker R, de Vogel D. The safety assessment of novel foods. Guidelines prepared by the ILSI Europe novel foods task force. Food Chem Toxicol 1996; 34: 931 - 40.
    • 3. Hammes WP, Tichaczek PS. The potential of lactic acid bacteria for the production of safe and wholesome food. Z Lebensm Unters Forsch 1994; 198: 193 - 201.
    • 4. Axelsson L. Lactic acid bacteria: classification and physiology. In: Salminen S, von Wright A, eds. Lactic acid bacteria, microbiology and functional aspects. New York: Marcel Dekker Inc, 1998: 1 - 73.
    • 5. Alander M, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A. Recovery of Lactobacillus rhamnosus GG from human colonic biopsies. Lett Appl Microb 1997; 24: 361 - 4.
    • 6. Molin G, Jeppson B, Johansson M, Ahrne S, Nobaek S, Stahl M, Bengmark S. Numerical taxonomy of Lactobacillus spp associated with healthy and diseased mucosa of the human intestines. J Appl Bacteriol 1993; 74: 314 - 23.
    • 7. Lee Y-K, Salminen S. The coming of age of probiotics. Trends Food Sci Techn 1995; 6: 241 - 5.
    • 8. Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Ped Gastroenterol Nutr 1995; 20: 333 - 8.
    • 9. Salminen S, Isolauri E, Salminen E. Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Anthonie van Leeuwenhoek 1996; 70: 347 - 58.
    • 10. Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988; 39: 435 - 7.
    • 11. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90 - 7.
    • 12. Gilliland SE. Health and nutritional benefits from lactic acid bacteria. FEMS Microbiol Rev 1990; 87: 175 - 88.
    • 13. Tang P, Foubister V, Pucciarelli MG, Finlay BB. Methods to study bacterial invasion. J Microbiol Meth 1993; 18: 227 - 40.
    • 14. Saxelin M, Chuang NH, Chassy B, Rautelin H, Ma¨kela¨ PH, Salminen S, Gorbach SL. Lactobacilli and bacteremia in southern Finland. 1989 - 1992. Clin Infect Dis 1996; 22: 564 - 6.
    • 15. Saxelin M, Rautelin H, Salminen S, Ma¨kela¨ PH. Safety of commercial products with viable Lactobacillus strains. Inf Dis Clin Pract 1996; 5: 331 - 5.
    • 16. Tuomola EM, Crittenden RG, Kirjavainen PV, Ouwehand AC, Morris LF, Peltonen KD, Playne MJ, Salminen SJ. Adhesion of clinical Lactobacillus isolates to human intestinal mucosal models. Abstract, SOMED meeting in Nizza, France 2 - 5 October, 1998, pp 151.
    • 17. Donohue DC, Deighton M, Ahokas JT, Salminen S. Toxicity of lactic acid bacteria. In: Saminen S, von Wright A, eds. Lactic acid bacteria. New York: Marcel Dekker Inc, 1993: 307 - 13.
    • 18. Donohue DC, Salminen S. Safety of probiotic bacteria. Asia Pac J Clin Nutr 1996; 5: 25 - 8.
    • 19. Dong MY, Chang TW, Gorbach SL. Effects of feeding Lactobacillus GG on lethal irradiation in mice. Diagn Microbiol Infect Dis 1987; 7: 1 - 7.
    • 20. Naaber P, Mikelsaar S, Salminen S, Mikelsaar M. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 1998; 47: 1 - 8.
    • 21. Ruseler-van Embden J, van Lieshout L, Marteau P. No degradation of intestinal mucus glycoproteins by Lactobacillus strain GG. Microecol Ther 1995; 25: 304 - 9.
    • 22. Hudault S, Lievin V, Bernet-Camard MF, Servin A. Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei strain GG against Salmonella typhimurium C5 infection. Appl Envir Micr 1997; 63: 513 - 8.
    • 23. Isolauri E, Kaila M, Arvola T, Majamaa H, Rantala I, Virtanen E, Arvilommi H. Diet during rotavirus enteritis affects jejunal permeability to macromolecules in suckling rats. Pediatr Res 1993; 33: 548 - 53.
    • 24. Wagner RD, Warner T, Roberts L, Farmer J, Balish E. Colonization of congenitally immunodeficient mice with probiotic bacteria. Inf Immun 1997; 65: 3345 - 51.
    • 25. Goldin B, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci 1992; 37: 121 - 8.
    • 26. Nanji AA, Khettry U, Sadrzadeh S. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver disease. Proc Soc Exp Biol Med 1994; 205: 243 - 7.
    • 27. Ruseler-van Embden JGH, van Lieshout LMC, Gosselink MJ, Marteau P. Inability of Lactobacillus casei strain GG, L. acidophilus, and Bifidobacterium bifidum to degrade intestinal mucus glycoproteins: clearing the way for mucosa-protective therapy. Scand J Gastroenterol 1995; 30: 675 - 80.
    • 28. Negretti F, Casetta P, Clerici-Bagozzi D, Marini A. Researches on the intestinal and systemic immune responses after oral treatments with Lactobacillus GG in the rabbit. Dev Physiopath Clin 1997; 7: 15 - 21.
    • 29. Wagner RD, Pierson C, Warner T, Dohnalek M, Farmer J, Roberts L, Hilty M. Biotherapeutic effects of probiotic bacteria on Candidiasis in immunodeficient mice. Infect Immun 1997; 65: 4165 - 72.
    • 30. Kirjavainen PV, Ouwehand AC, Isolauri E, Salminen SJ. The ability of probiotic bacteria to bind to human intestinal mucus. FEMS Mirobiol Lett 1998 (in press).
    • 31. Lehto E, Salminen S. Adhesion of two Lactobacillus strains, one Lactococcus strain and one Propionibacterium strain to cultured human intestinal Caco-2 cell line. Biosci Microflora 1997; 16: 13 - 7.
    • 32. Tuomola E, Salminen SJ. Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures. Int J Food Microbiol 1998; 41: 45 - 51.
    • 33. Marteau P, Pochart P, Bouhnik Y, Rambaud JC. Fate and effects of some trasiting micro-organisms in the human gastrointestinal tract. World Rev Nutr Diet 1993; 74: 1 - 21.
    • 34. Marteau P, Gerhardt MF, Myara A, Bouvier E, Trivin F, Rambaud JC. Bifidobacteria and lactobacilli ingested in fermented dairy products can metabolize bile salts in the human small intestine. Microbiol Ecol Health Dis 1995; 8: 151 - 7.
    • 35. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human necrosis factor alpha, interleukin 6, and interleukin 10 is induced by lactic acid bacteria. Infect Immunol 1996; 64: 5403 - 5.
    • 36. Perdigon G, De Jorrat MEB, De Petrino SF, De Budeguer MV. Effect of oral administration of Lactobacillus casei on various biological functions of the host. Food Agric Immunol 1991; 3: 93 - 102.
    • 37. McConnel MA, Mercer AA, Tannock GW. Transfer of plasmid pAMb1 between members of the normal microflora inhabiting the murine digestive tract and modification of the plasmid in a Lactobacillus reuteri host. Microb Ecol Health Dis 1991; 4: 343 - 55.
    • 38. Sartor RB, Bond TM, Schwab JH. Systemic uptake and intestinal inflammatory effects of luminal bacterial cell wall polymers in rats with acute colonic injury. Infect Immunol 1988; 56: 2101 - 8.
    • 39. Blancuzzi V, Roberts ED, Wilson D, Fryer LR, O'Byme EM, DiPasquale G. Pathogenesis of Lactobacillus casei induced polyarthritis in Lewis rats: 1. Time related changes in hisotpahological scores and hematology. Agents Actions 1993; 39 special conference, C183 - 5.
    • 40. Pelto L, Salminen S, Lilius E-M, Nuutila J, Isolauri E. Milk hypersensitivity - key to poorly defined gastrointestinal symptoms in adults. Allergy 1998; 53: 307 - 10.
    • 41. Wheeler G, Shema S, Bogle M, Shirrel A, Burks W, Pittler A, Helm R. Immune and clinical impact of Lactobacillus acidophilus on asthma. Ann Allergy Asthma Immunol 1997; 79: 229 - 33.
    • 42. Fukushima Y, Kawata Y, Hara H, Terada A, Mitsuoka T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998; 42: 39 - 44.
    • 43. Clewell DD, Yagi Y, Dunny GM, Schultz SK. Characterization of three plasmid deoxyribonucleic acid molecules in a strain of Streptococcus faecalis: identification of a plasmid determining erythromycin resistance. J Bacteriol 1974; 117: 283 - 9.
    • 44. Leblanc DJ, Lee LN. Physical and genetic analysis of streptococcal plasmid pAMb1 and cloning of its replication region. J Bacteriol 1984; 157: 445 - 53.
    • 45. Horodniceanu T, Bouanschaud DH, Bieth G, Chabbert YA. R plasmids in Streptococcus agalactiae (group B). Antimicrob Agents Chemother 1976; 10: 795 - 801.
    • 46. Evans RP, Macrina FL. Streptococcal R plasmid pIP501: endonuclease site map, resistance determinant location, and construction of novel derivatives. J Bacteriol 1983; 154: 1347 - 55.
    • 47. von Wright A, Sibakov M. Genetic modification of lactic acid bacteria. In: Salminen S, von Wright A, eds. Lactic acid bacteria. Microbiology and functional aspects. New York: Marcel Dekker Inc, 1998: 161 - 210.
    • 48. Morelli L, Sarra PG, Bottazzi V. In vivo transfer of pAMb1 from Lactobacillus reuteri to Enterococcus faecalis. J Appl Bacteriol 1988; 65: 371 - 5.
    • 49. Salminen S, von Wright A, Morelli L, Marteau P, Brassard D, de Vos W, Fonde´n R, Saxelin M, Collins K, Mogensen G, Birkeland SE, Mattila-Sandholm T. Demonstration of safety of probiotics - a review. Int J Food Microbiol (in press).
    • 50. Lorenz M, Wackernagel W. Bacterial gene transfer by natural genetic transformation in the environment. Microbiol. Rev. 1994; 58: 563 - 602.
    • 51. Schubbert R, Lettmann C, Doerfler W. Ingested foreign (phage M13) DNA survives transiently in the gastrointestinal tract and enters the bloodstream of mice. Molecular and General Genetics (Mol. Gen. Genet) 1994; 242: 495 - 504.
    • 52. Schubbert R, Renz D, Schmitz B, Doerfler W. Foreign (M13) DNA ingested by mice reaches peripheral leucocytes, spleen and liver via the intestinal wall mucosa and can be covalently linked to mouse DNA. Proc. Natl. Acad. Sci. USA. 1997; 94: 961 - 966.
    • 53. Handwereger S, Pucci MJ, Volk KJ, Liu J, Lee MS. Vancomycin-resistant Leuconostoc mesenteroides and Lactobacillus casei synthesize cytoplasmic peptidoglycan precursosrs that terminate in lactate. J Bacteriol 1994; 176: 260 - 4.
    • 54. Billot-Klein D, Gutmann L, Sablee´ S, Guillet E, van Heijenoort J. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin resistant VANB type Enterococcus D366 and of the naturally glycopeptide resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconsotoc mesenteroides, and Enterococcus gallinarum. J Bacteriol 1994; 176: 2398 - 405.
    • 55. Adams MR, Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol 1995; 27: 263 - 4.
    • 56. Aguirre M, Collins MD. Lactic acid bacteria and human clinical infection. J Appl Bacteriol 1993; 75: 95 - 107.
    • 57. Gasser F. Safety of lactic acid bacteria and their occurrence in human clinical infections. Bull Inst Pasteur 1994; 92: 45 - 67.
    • 58. Gallemore GH, Mohon RT, Ferguson DA. Lactobacillus fermentum endocarditis involving a native mitral valve. J Terun Med Assoc 1995; 88: 306 - 8.
    • 59. Patel R, Cockerill FR, Porayko MK, Osmon DR, Ilstrup DM, Kenting MR. Lactobacillemia in liver transplant patients. Clin Infect Dis 1994; 18: 207 - 12.
    • 60. Kalima P, Masterton RG, Roddie PH, Thomas AE. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996; 32: 165 - 7.
    • 61. Horwitch CA, Furseth HA, Larson AM, Jones TL, Olliffe JF, Spach DH. Lactobacillemia in three patients with AIDS. Clin Infect Dis 1995; 21: 1460 - 2.
    • 62. Pelletier C, Bouley C, Bourliov P, Carbon C. Evaluation of safety properties of Lactobacillus strains by using an experimental model of endocarditis in rabbit. Abstract, SOMED Meeting, Paris, 1996.
    • 63. Pletinex M, Legein J, Vandenplas Y. Fungernia with Saccharomyce boulardii in a 1-year old girl with protracted diarrhoea. J Ped Gastroenterol Nutr 1995; 21: 113 - 5.
    • 64. MacFarland L, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ercol Health Dis 1993; 6: 157 - 71.
    • 65. Donohue D, Salminen S, Marteau P. Safety of probiotic bacteria. In: Salminen S, von Wright A, eds. Lactic acid bacteria, microbiology and functional aspects. New York: Marcel Dekker Inc, 1998: 369 - 84.
    • 66. Oakey HJ, Harty DWS, Knox KW. Enzyme production by lactobacilli and the potential link with infective endocarditis. J Appl Bacteriol 1995; 78: 142 - 8.
    • 67. Wolf BW, Garleb KA, Ataya DG, Casas IA. Safety and tolerance of Lactobacillus reuteri in healthy adult male subjects. Microb Ecol Health Dis 1995; 8: 41 - 50.
    • 68. Okitsu-Negishi S, Nakano I, Suzuki K, Hashira S, Abe T, Yoshino K. The induction of cardiangitis by Lactobacillus casei cell wall in mice I. The cytokine production from murine macrophages by Lactobacillus casei cell wall extracts. Clin Immunol Immunopathol 1996; 78: 30 - 40.
    • 69. Zunic P, Lacotte J, Pegoix M, Buteux G, Leroy G, Mosquett B, Molin M. Fonge´rnie Saccharomyces boulardii. Therapie 1991; 46: 497 - 501.
    • 70. ILSI Europe. A scientific basis for regulations on pathogenic micro-organisms in foods Summary of a workshop held in May 1993 and organised by the Scientific Committee on Microbiology. ILSI Press, Brussels 1993.
    • 71. Donohue DC, Salminen S. Safety of Lactobacillus GG (ATCC 53103). Nutr Today 1996; 31: 12 - 5.
    • 72. Tynkkynen S, Singh K, Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (6an) genes. Int J Food Microbiol 1998; 41: 195 - 204.
    • 73. Dhodapkar KM, Henry NK. Leuconostoc bacteriemia in an infant with short-gut syndrome: case report and literature review. Mayo Clin Proc 1996; 71: 1171 - 4.
    • 74. Marteau P, Vaerman JP, Dehenin JP, Bord S, Brassart D, Pochart P, Desjeux JF, Rambaud JC. Effect of intrajejunal perfusion and chronic ingestion of Lactobacillus acidophilus strain La1 on serum concentrations and jejunal secretions of immunoglobulins and serum proteins in healthy humans. Gastrointest Clin Biol 1998 (in press).
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from